UVEAL MELANOMA
Clinical trials for UVEAL MELANOMA explained in plain language.
Never miss a new study
Get alerted when new UVEAL MELANOMA trials appear
Sign up with your email to follow new studies for UVEAL MELANOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Experimental vaccine aims to stop rare eye cancer from returning
⭐️ VACCINE ⭐️ CompletedThis phase 3 trial tests a personalized vaccine made from a patient's own immune cells and tumor RNA to prevent uveal melanoma from coming back after surgery. The study includes 200 people with a high-risk genetic type (monosomy 3) and no signs of spread. Half receive the vaccine…
Matched conditions: UVEAL MELANOMA
Phase: PHASE3 • Sponsor: University Hospital Erlangen • Aim: ⭐️ VACCINE ⭐️
Last updated May 13, 2026 16:01 UTC
-
Cancer drug falls short in rare eye melanoma trial
Disease control CompletedThis study tested the drug sorafenib in 32 adults with uveal melanoma that had spread to other parts of the body. The goal was to see if the drug could stop tumors from growing for at least 24 weeks. Sorafenib is taken as a daily pill and works by blocking signals that help cance…
Matched conditions: UVEAL MELANOMA
Phase: PHASE2 • Sponsor: University Hospital, Caen • Aim: Disease control
Last updated May 26, 2026 03:17 UTC
-
New immune cell attack shows promise for tough melanomas
Disease control CompletedThis early-phase study tested a new treatment called TBio-4101 for people with advanced melanoma that had stopped responding to standard therapies. The treatment uses a patient's own immune cells (TILs) that are selected and grown in the lab, then given back after chemotherapy to…
Matched conditions: UVEAL MELANOMA
Phase: PHASE1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated May 20, 2026 11:55 UTC
-
New hope for rare eye cancer: trial tests targeted therapy
Disease control CompletedThis study tested a new drug called IMCgp100 in 378 adults with a specific type of advanced eye cancer (uveal melanoma) that had not been treated before. Participants received either IMCgp100 or one of three standard treatments. The main goal was to see if IMCgp100 helped people …
Matched conditions: UVEAL MELANOMA
Phase: PHASE2 • Sponsor: Immunocore Ltd • Aim: Disease control
Last updated May 20, 2026 11:54 UTC
-
Can extra support ease the emotional burden of advanced eye cancer?
Symptom relief CompletedThis study looked at whether adding supportive care early on helps meet the psychological needs of people with metastatic uveal melanoma, a rare eye cancer that has spread. 162 adults took part, receiving either standard cancer care alone or with early supportive care. The goal w…
Matched conditions: UVEAL MELANOMA
Phase: NA • Sponsor: Institut Curie • Aim: Symptom relief
Last updated May 26, 2026 03:05 UTC
-
Blood test may predict success of liver surgery for rare eye cancer
Knowledge-focused CompletedThis study looked at 60 people with uveal melanoma that spread to the liver and who were eligible for surgery to remove it. Researchers measured circulating tumor DNA in the blood before and after surgery to see if it could predict whether all cancer was removed. The goal was to …
Matched conditions: UVEAL MELANOMA
Phase: NA • Sponsor: Institut Curie • Aim: Knowledge-focused
Last updated May 19, 2026 12:01 UTC